Morrison & Foerster represented Ally Bridge Group, a global life-science dedicated investment group, as the lead investor in connection with Pulmonx Corporation’s oversubscribed US$65 million equity financing.
Based in Redwood City, California, Pulmonx is the world leader in interventional pulmonology diagnostics, planning tools, and treatments for obstructive lung disease. The company develops and markets minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. The new financing positions Pulmonx to lead the emerging global field of interventional pulmonology.
The MoFo team was led by Hong Kong partner Thomas Chou, co-chair of the firm’s Asia Private Equity Practice and head of the China M&A group, and included San Francisco corporate associates Sara Ayse Uz and Ana Belen Vinueza, and technology transactions associate Dr. Can Cui. Palo Alto patent partner Janet Xiao and San Diego patent associate Bu Yin, as well as Boston finance partner Alexander Rheaume and associate Stephen Queenan, made significant contributions to the deal.
Read the related press release.
